Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Dr. Reddy`s Laboratories, Ltd
Transcript
Dr. Reddy's Laboratories, Ltd Generics Drug Discovery Biopharmaceuticals DELEGATE(S) Shalabh Sachdeva K. Sumit Kumar Cartikeya Reddy Sumera Hasham Atin Tomar 8-2-337, Road No 3, Banjara Hills Hyderabad 500 034 India www.drreddys.com Ownership: Public MISSION/BACKGROUND Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. As a fully integrated pharmaceutical company, our purpose is to provide affordable and innovative medicines through our three core businesses: Pharmaceutical Services and Active Ingredients, comprising our Active Pharmaceuticals and Custom Pharmaceuticals businesses; Global Generics, which includes branded and unbranded generics; and Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations, and Generic Biopharmaceuticals. Our products are marketed globally, with a focus on India, US, Europe and Russia. Dr. Reddy’s conducts NCE research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation. Bombay Stock Exchange: RDY Our strong portfolio of businesses, geographies and products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world, regardless of geographic and socio-economic barriers. ALLIANCES The biologics division of Dr Reddy's is in alliance with several partners across several parts of the globe to commercialize its Biosimilar products - Rituximab, Filgrastim, PEG-Filgrastim and Darbepoetin. These alliances cover the emerging markets of Latin America, Middle East & North Africa and South East Asia currently. The company is currently exploring opportunities for partnership for the regulated markets of Europe, US and Japan PRODUCTS Name Phase Indication Rituximab On Market NHL, CLL, RA Darbepoetin On Market Chemotherapy Induced Anemia, Chronic Kidney Disease Anemia Filgrastim On Market CT Neutropenia, Neutropenia PEG-Filgrastim On Market CT Neutropenia 16 – Company Profiles
